Xeroderma Pigmentosum Clinical Trial
Official title:
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00555633 -
Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients
|
N/A | |
| Recruiting |
NCT05484570 -
Natural History Study for DNA Repair Disorders
|
||
| Active, not recruiting |
NCT00001813 -
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
|
||
| Completed |
NCT03445052 -
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions
|
N/A | |
| Recruiting |
NCT05370235 -
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
|
Phase 2 | |
| Unknown status |
NCT01123694 -
Xeroderma Pigmentosum Patient Experiences
|
N/A | |
| Withdrawn |
NCT04500548 -
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
|
Phase 1 | |
| Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
| Completed |
NCT00046189 -
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
|